Canakinumab allows discontinuation of corticosteroids in patients with SJIA
Successful tapering achieved within 20 weeks
Published 2013-06-13 · Original archive entry · Explore research explainers
Madrid, Spain, 13 June 2013: Study findings first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the efficacy of canakinumab at tapering corticosteroid (CS) use in patients with SJIA.
Successful CS tapering was achieved within 20 weeks in almost half of patients (44.5%, p END
Successful CS tapering was achieved within 20 weeks in almost half of patients (44.5%, p END